- Home
- PBPB vs CRVS Comparison
PBPB vs CRVS Comparison
Compare PBPB & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- CRVS
- Stock Information
- Founded
- PBPB 1977
- CRVS 2014
- Country
- PBPB United States
- CRVS United States
- Employees
- PBPB N/A
- CRVS N/A
- Industry
- PBPB Restaurants
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- CRVS Health Care
- Exchange
- PBPB Nasdaq
- CRVS Nasdaq
- Market Cap
- PBPB 305.0M
- CRVS 305.4M
- IPO Year
- PBPB 2013
- CRVS 2016
- Fundamental
- Price
- PBPB $12.94
- CRVS $5.75
- Analyst Decision
- PBPB Strong Buy
- CRVS Strong Buy
- Analyst Count
- PBPB 2
- CRVS 4
- Target Price
- PBPB $17.50
- CRVS $15.00
- AVG Volume (30 Days)
- PBPB 257.0K
- CRVS 518.7K
- Earning Date
- PBPB 08-06-2025
- CRVS 08-07-2025
- Dividend Yield
- PBPB N/A
- CRVS N/A
- EPS Growth
- PBPB N/A
- CRVS N/A
- EPS
- PBPB 0.35
- CRVS N/A
- Revenue
- PBPB $469,138,000.00
- CRVS N/A
- Revenue This Year
- PBPB $5.28
- CRVS N/A
- Revenue Next Year
- PBPB $4.30
- CRVS N/A
- P/E Ratio
- PBPB $37.36
- CRVS N/A
- Revenue Growth
- PBPB N/A
- CRVS N/A
- 52 Week Low
- PBPB $7.27
- CRVS $2.54
- 52 Week High
- PBPB $13.67
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- PBPB 57.95
- CRVS 65.10
- Support Level
- PBPB $12.78
- CRVS $5.28
- Resistance Level
- PBPB $13.18
- CRVS $5.64
- Average True Range (ATR)
- PBPB 0.38
- CRVS 0.30
- MACD
- PBPB 0.05
- CRVS 0.03
- Stochastic Oscillator
- PBPB 81.10
- CRVS 77.70
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).